Myosin Activators

Giuseppe Rosano, Piotr Ponikowski

Abstract


Inotropes historically all increased intra-cellular calcium levels and they commonly caused intracellular Ca2+ overload and triggered malignant arrhythmias. The myosin activators, such as Omecamtiv Mecarbil (OM), increase myosin activity and function, and modify acto-myosin interaction through calcium-independent mechanisms. OM is a selective cardiac myosin activator that binds specifically the catalytic domain of cardiac myosin without any significant effect over other types of non-cardiac myosin. It increases the speed of ATP hydrolysis and, therefore, accelerates the transition rate to a strongly bound force-producing state, increases the number of myosin heads that interact with actin filaments and increases the proportion of time they are in a force producing state. OM decreases the inefficient use of non-contractile energy. OM has been studied in 4 phase II clinical trials with more than 1,300 patients with heart failure. The GALACTIC-HF trial is a nearly 8,000 patient HFrEF mortality/morbidity trial which started recruiting in January 2017 and should be completed soon.


Keywords


Hart Failure; Myosin activators

References


Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016.

Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:1810-52.

Benjamin EJ, Blaha MJ, Chiuve SE et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017;135:e146-e603.

Hasenfuss G, Teerlink JR. Cardiac inotropes: current agents and future directions. Eur Heart J 2011;32:1838-45.

Malik FI, Morgan BP. Cardiac myosin activation part 1: from concept to clinic. J Mol Cell Cardiol 2011;51:454-61.

Spudich JA. How molecular motors work. Nature 1994;372:515-8.

Malik FI, Hartman JJ, Elias KA et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 2011;331:1439-43.

Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011;378:667– 5.

Cleland JG, Teerlink JR, Senior R et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011;378:676-83.

Greenberg BH, Chou W, Saikali KG, Escandón R, Lee JH, Chen MM, Treshkur T, Megreladze I, Wasserman SM, Eisenberg P, Malik F, Wolff AA, Shaburishvili T. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail. 2015;3:22–9.35.

Teerlink JR, Felker GM, McMurray JJ, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JG, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, Wasserman SM ATOMIC-AHF Investigators. Acute treatment with omecamtiv mecarbil to Increase contractility in acute heart failure: the ATOMIC-AHF Study. J Am Coll Cardiol. 2016;67:144

Teerlink JR, Felker GM, McMurray JJ et al. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 2016;388:2895-2903.

Registrational Study with Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure with Reduced Ejection Fraction (GALACTIC-HF) ClinicalTrials.gov Identifier: NCT02678923.

Shewan LG, Coats AJS, Henein MY. Authors’ Responsibilities and Ethical Publishing. International Cardiovascular Forum Journal 2018;13:3-4, DOI: 10.17987/icfj.v13i0.525




DOI: https://doi.org/10.17987/icfj.v18i0.611

Copyright (c) 2019 The author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.